November 2024
Kyowa Kirin Invests $330M in Kura’s Leukemia Drug, Gaining Shared Rights Ahead of FDA Submission
Kyowa Kirin, Kura, leukemia drug, FDA submission, pharmaceutical investment
Carolyn Bertozzi’s Valora Therapeutics Launches with $30M Seed Round to Develop Sugar-Based Immunotherapies
Carolyn Bertozzi, Valora Therapeutics, immunotherapy, sugar-based treatments, biotech startup, $30M seed round
Pfizer Expands Collaboration with Flagship Pioneering, Adding Ampersand Biomedicines and Montai Therapeutics
Pfizer, Flagship Pioneering, Ampersand Biomedicines, Montai Therapeutics, strategic partnership, drug development, obesity, non-small cell lung cancer
NewAmsterdam’s CETP Inhibitor Obicetrapib Achieves Phase 3 Success but Fails to Meet Investor Expectations
NewAmsterdam Pharma, CETP inhibitors, obicetrapib, cholesterol-lowering drugs, Phase 3 trials, investor expectations, LDL cholesterol reduction
Medtronic Advances Diabetes Management with FDA Clearance of InPen App and Launch of Smart MDI System
Medtronic, FDA clearance, InPen app, Smart MDI system, diabetes management, insulin therapy, continuous glucose monitoring (CGM), Simplera CGM
Grifols Rejects Brookfield’s €6.45 Billion Takeover Bid, Citing Undervaluation
Grifols, Brookfield, takeover offer, undervaluation, private equity
FDA Raises Safety Concerns Over AstraZeneca’s Andexxa Ahead of Advisory Committee Meeting
AstraZeneca, Andexxa, FDA, safety concerns, bleeding reversal agent, advisory committee meeting
Eli Lilly and Johnson & Johnson Sue US Government Over 340B Rebate Models
340B Drug Pricing Program, Eli Lilly, Johnson & Johnson, HRSA, rebate models, pharmaceutical pricing, healthcare litigation
Dr. Mehmet Oz Nominated to Lead Centers for Medicare and Medicaid Services
Dr. Mehmet Oz, Medicare, Medicaid, Centers for Medicare and Medicaid Services, Trump nomination, healthcare leadership
Pfizer Appoints Chris Boshoff as New Chief Scientific Officer and President of Research & Development
Pfizer, Chris Boshoff, Chief Scientific Officer, President of Research & Development, Mikael Dolsten, Leadership Changes, Oncology, R&D